Fernandez sees a total addressable market of $140 billion to support patients with obesity.
He expects there is a potential for GLP-1 drugs to become as common and widely used, much like statins are used to lower cholesterol.
Morgan Stanley's Flynn estimates a 30% share of the diabetes market would generate $109 billion on a worldwide basis for GLP-1 drugs.
Layer in a 15% to 30% share of the obesity market and that equates to worldwide sales of $97.4 billion to $194.8 billion.
Guggenheim's estimates also assume that oral GLP-1 drugs that are currently in development are able to come to market a few years from now.
Persons:
Seamus Fernandez, Fernandez, Lilly, Eli Lilly, Morgan Stanley, Terence Flynn, Eli Lilly's Mounjaro, Insulet, Canaccord, William Plovanic, Plovanic, It's, Morgan Stanley's Flynn, Flynn, Novo, Michael Bloom
Organizations:
Wall, Novo, American Heart Association, Food and Drug Administration, Novo Nordisk, Iqvia, Disease Control
Locations:
GLP